P236: Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study by John Bernat, Myrl Holida, Stephen Waldek, William Wilcox, Nicola Longo, Ozlem Goker-Alpan, Eric Wallace, Patrick Deegan, Camilla Tondel, François Eyskens, Ulla Feldt-Rasmussen, Derralynn Hughes, Antonio Pisani, Ankit Mehta, Khan Nedd, David Warnock, Giovanni Piotti, Meng Wang, Einat Almon-Brill, Sari Alon, Raul Chertkoff, Ales Linhart

Get full text